Compare BIO-TECHNE Corp (TECH) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs State Street SPDR S&P Homebuilders ETF — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while State Street SPDR S&P Homebuilders ETF trades at $95 (market cap $1.53B). The key difference: BIO-TECHNE Corp is far larger — about 7.4× State Street SPDR S&P Homebuilders ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| TECH | XHB | |
|---|---|---|
Market Cap | $11.36B | $1.53B |
Volume | 5,390,331 | 2,228,322 |
Sector | Health | Broad Market / Factor |
52-Week High | $72.61 | $121.36 |
52-Week Low | $43.31 | $94.86 |
Typical Hold Time | 63 Days | 33 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
XHB (SPDR S&P Homebuilders ETF) trades at $94.89, down 2.55% today amid a bearish technical signal from moving averages, though oscillators are neutral. The ETF, tracking homebuilder stocks, faces headwinds from rising mortgage rates but benefits from positive housing legislation and institutional interest. Key support sits at $94, with resistance at $95.
Outlook is mixed: potential upside exists from housing policy tailwinds and undervalued sector signals, but high rates and volatile sales data pose near-term risks. Investors should weigh macroeconomic sensitivity against long-term housing demand drivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
